medigraphic.com
ISSN 1561-3127 (Electronic)
ISSN 0864-3466 (Print)

2014, Number 4

<< Back Next >>

Revista Cubana de Salud Pública 2014; 40 (4)

Customized medicine, genomic revolution and the national health care system

Hernández BJC, Serrano BO

Language: Spanish
References: 50
Page: 379-391
PDF size: 115.99 Kb.


ABSTRACT

Deepening into the knowledge of the molecular mechanisms of the health/disease process has made many scientific advances to find a place into the clinical practice, as is the case of stem cells therapy in Cuba. The results derived from the sequencing of the human genome, as well of other species, have had an impact in the improvement of diagnoses and therapies; however, within the Cuban national health system the applications of genomic technologies are not widespread. Despite the fact that this new medicine still needs to accumulate much more evidence supporting its safety and efficacy, it is urgent to design a customized strategy by the Cuban Ministry of Public Health towards the assessment of current and potential uses of genomic medicine for the benefit of the population's health. Among other actions, this paper submitted the proposal of the creation of a multi-institutional and intersectoral taskforce to study the clinical, technological, regulatory and bioethical dimensions of genomic medicine. It is mandatory to train both undergraduate students and staff since they will be responsible to introduce and extend such technologies in their professional practice. It is already possible to make up cohorts resembling as much as possible the Cuban population, to study them and to collect and preserve their samples in biobanks established for such purposes.


REFERENCES

  1. Chan IS, Ginsburg GS. Personalized Medicine: Progress and Promise. Annu. Rev. Genomics Hum Genet. 2011;12:217-44.

  2. Barrios López Y, Perera Fernández F, Carvajal Beltrán II, Pérez Rodríguez A. Pesquisa de cáncer de próstata en 8 áreas de salud de la provincia de Santiago de Cuba. MEDISAN. 2012 [citado 31 Mar 2014];16(3):376-382. Disponible en: http:/www.scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029- 30192012000300010&lng=es

  3. Guang Li S, Li L. Targeted therapy in HER2-positive breast cancer. Biomed Rep. 2013 [cited 2014 Mar 31];1(4):499-505. Available from: http://www.spandidospublications. com/10.3892/br.2013.95

  4. Hood L, Auffray C. Participatory medicine: a driving force for revolutionizing healthcare. Genome Med. 2013 [cited 2014 Mar 31];5(12):110. Available from http://www.genomemedicine.com/content/5/12/110

  5. Ikawa S, Fukui M, Ueyama Y, Tamaoki N, Yamamoto T, Toyoshima K. B-raf, a new member of the raf family, is activated by DNA rearrangement. Mol Cell Biol. 1988 [cited 2014 Mar 31];8:2651-4. Available from: http://www,mcb.asm.org/content/8/6/2651.long

  6. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med. 2011 [cited 2014 Mar 31];364:2507-16. Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa1103782#t=articleTop

  7. Liu W, Medeiros LJ, Lin P, Romaguera JE, Wang SA, Jorgensen JL. Usefulness of flow cytometric immunophenotyping for bone marrow staging in patients with mantle cell lymphoma after therapy. Am J Clin Pathol. 2012 [cited 2014 Mar 31];137(4):634-40. Available from: http:/www.ajcp.ascpjournals.org/content/137/4/634.long

  8. Elli M, Yilmaz S, Aydin R, Murat S, Bilgici MC, Dagdemir A. Rituximab used in three cases with relapsed non-Hodgkin's lymphoma. Mol Clin Oncol. 2013 [cited 2014 Mar 31];1(3):550-2. Available from: http://www.spandidospublications. com/mco/1/3/550

  9. Hernández Ramírez P. Medicina regenerativa y aplicaciones de las células madre: una nueva revolución en medicina. Rev Cubana Med. 2011 [citado 3 May 2014 2014 1];50(4):338-40. Disponible en: http://www.scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034- 75232011000400001&lng=es

  10. Álvarez López A, Ortega González C, García Lorenzo Y, Arias Sifontes J, Ruiz de Villa Suárez A. Plasma rico en plaquetas en pacientes con gonartrosis. Rev Arch Méd Camagüey. 2013 [citado 1 Abr 2014];17. Disponible en: http://www.revistaamc.sld.cu/index.php/amc/article/view/1353/466

  11. Andia I, Maffulli N. Platelet-rich plasma for managing pain and inflammation in osteoarthritis. Nature Rev Rheumatol. 2013 [cited 2014 Abr 1];9:721730. Available from: http://www.nature.com/nrrheum/journal/v9/n12/full/nrrheum.2013.141.html Revista Cubana de Salud Pública. 2014;40(4):379-391 http://scielo.sld.cu 388

  12. Franco Mora M del C, García Hadfeg O, Alí Pérez N, Olivares Louhau E M, Rodríguez Sánchez O. Exéresis de un tatuaje y terapia regenerativa con plaquetas. MEDISAN. Feb [citado 1 Abrl 2014];7(2):98-403. Disponible en: http://www.scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029- 30192013000200018&lng=es

  13. González-González JA, Gámez-Pérez A, Rodríguez-Orta C, Cruz-Sánchez P, López-González El, González-Cordero F et al. Terapia celular en fractura del fémur. Rev Cubana Hematol Inmunol Hemoter. 2012 [citado 1 Abr 2014];28(1):84-90. Disponible en: http:/www.scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 02892012000100010&lng=es

  14. Check Hayden E. Hopes of HIV cure in 'Boston patients' dashed. Nature. 2013 [cited 2014 Abr 1]. Available from: http://www.nature.com/news/hopes-of-hivcure- in-boston-patients-dashed-1.14324

  15. Lesk A. Introduction to Bioinformatics. 4th ed. Londres: Oxford University; 2013. doi: 10.1038/nature.2013.14324Press.

  16. The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012 [cited 2014 Abr 1];491:56-65. Available from: http://www.nature.com/nature/journal/v491/n7422/full/nature11632.html

  17. Pang AW, MacDonald JR, Pinto D, Wei J, Rafiq MA, Conrad DF, et al. Towards a comprehensive structural variation map of an individual human genome. Genome Biol. 2010 [cited 2014 Abr 1];11(5):R52. Available from: http://www.genomebiology.com/2010/11/5/R52

  18. Cima I, Schiess R, Wild P, Kaelin M, Schüffler P, Lang V, et al. Cancer geneticsguided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. PNAS. 2011 [cited 2014 Abr 1];108(8):3342-7. Available from: http://www.pnas.org/content/108/8/3342.full

  19. Sebastiani P, Solovieff N, DeWan AT, Walsh KM, Puca A, Hartley SW. Genetic Signatures of Exceptional Longevity in Humans. PLoS One. 2012 [cited 2014 Abr 1] 7(1):e29848. Available from: http://www.europepmc.org/articles/PMC3261167

  20. Loscalzo J. Personalized cardiovascular medicine and drug development: time for a new paradigm. Circulation. 2012 [cited 2014 Abr 1];125(4):638-45. Available from: http://www.circ.ahajournals.org/content/125/4/638.full?sid=b1ed667e-9e68- 4dce-b077-8220911d6e61

  21. Mayer C, Popanda O, Greve B, Fritz E, Illig T, Eckardt-Schuppf F, et al. A radiation-induced gene expression signature as a tool to predict acute radiotherapyinduced adverse side effects. Cancer Lett. 2011 [cited 2014 Abr 1];302(1):20-8. Available from: http://www.sciencedirect.com/science/article/pii/S0304383510005653

  22. Mayer AN, Dimmock DP, Arca MJ, Bick DP, Verbsky JW, Worthey EA, et al. A timely arrival for genomic medicine. Genetics Med. 2011 [cited 2014 Abr 1];13(3). Available from: http://www.nature.com/gim/journal/v13/n3/full/gim9201137a.html

  23. Worthey EA, Mayer AN, Syverson GD, Helbling D, Bonacci BB, Decker B, et al. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet Med. 2011 [cited 2014 Abr 1];13(3):255-62. Available from: http://www.nature.com/gim/journal/v13/n3/full/gim9201146a.html

  24. Hood L, Flores M. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. New Biotechnol. 2012 [cited 2014 Abr 1];29(6):13-624. Available from: http://www.sciencedirect.com/science/article/pii/S1871678412000477

  25. Meléndez-Herrada E, Ramírez M, Sánchez Dorantes BG, Cervantes E. Aportaciones de la genómica y la bioinformática al nuevo virus de la influenza A (H1N1) y su impacto en la medicina. Rev Fac Med UNAM. 2010;53(2):76-82.

  26. Driguez P, Doolan DL, Loukas A, Felgner PL, McManus DP. Schistosomiasis vaccine discovery using immunomics. Parasites Vect. 2010;3:4.

  27. Philippe N, Legendre M, Doutre G, Couté Y, Poirot O, Lescot M, et al. Pandoraviruses: amoeba viruses with genomes up to 2.5 Mb reaching that of parasitic eukaryotes. Science. 2013;341(6143):281-6.

  28. González-Candelas F, Bracho MA, Wróbel B, Moya A. Molecular evolution in court: analysis of a large hepatitis C virus outbreak from an evolving source. BMC Biol. 2013 [cited 2014 Abr 1];11:76. Available from: http://www.biomedcentral.com/1741-7007/11/76.

  29. The Human Microbiome Project Consortium. A framework for human microbiome research. Nature. 2012 [cited 2014 Abr 1];486:215-21. Available from: http://www.nature.com/nature/journal/v486/n7402/full/nature11209.html

  30. The Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012 [cited 2014 Abr 1];486:207-14. Available from: http://www.nature.com/nature/journal/v486/n7402/full/nature11234.html

  31. Jakobsson HE, Abrahamsson TR, Jenmalm MC, Harris K, Quince C, Jernberg C, et al. Decreased gut microbiota diversity, delayed Bacteroidetes colonization, and reduced Th1 responses in infants delivered by Caesarean section. Gut. 2014;63(4):559-66. doi: 10.1136/gutjnl-2012-303249.

  32. Haiser HJ, Gootenberg DB, Chatman K, Sirasani G, Balskus EP, Turnbaugh PJ. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science. 2013;341(6143):295-8.

  33. Ritchie MD. The success of pharmacogenomics in moving genetic association studies from bench to bedside: study design and implementation of precision medicine in the post-GWAS era. Hum Genet. 2012;131:1615-26.

  34. Hershfield MS, Callaghan JT, Tassaneeyakul W, Mushirod T, Thorn CF, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing. Clin Pharmacol Therapeut. 2013;93(2):153-8. Revista Cubana de Salud Pública. 2014;40(4):379-391 http://scielo.sld.cu 390

  35. Verez Bencomo V, Fernández Santana V, Hardy E, Toledo ME, Rodríguez MC, Heynngnezz L, et al. A synthetic conjugate polysaccharide vaccine against haemophilus influenzae type b. Science. 2004;305(5683):522-5.

  36. Solomón MT, Selva JC, Figueredo J, Vaquer J, Toledo C, Quintanal N, et al. Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial. BMC Cancer. 2013 [cited 2014 Abr 1];13:299. Available from: http://www.biomedcentral.com/1471- 2407/13/299

  37. Rodeiro I, Remírez-Figueredo D, García-Mesa M, Dorado P, LLerena A. CEIBA Pharmacogenetics in Latin American populations: regulatory aspects, application to herbal medicine, cardiovascular and psychiatric disorders. Drug Metab Drug Interact. 2012;27(1):57-60.

  38. Teruel BM, Rodríguez JJ, McKeigue P, Mesa TTC, Fuentes E, Cepero A AV, et al. Interactions between genetic admixture, ethnic identity, APOE genotype and dementia prevalence in an admixed Cuban sample; a cross-sectional population survey and nested case-control study. BMC Med Genet. 2011 [cited 2014 Abr 1];12:43. doi: 10.1186/1471-2350-12-43. Available from: http://www.biomedcentral.com/1471-2350/12/43

  39. Ochagavía ME, Miranda J, Nazábal M, Martin A, Novoa LI, Bringas R, et al. Methodology based on molecular interactions and pathways to find candidate genes associated to diseases: its application to schizophrenia and Alzheimer's disease. J Bioinformatics Computat Biol. 2011;9 (4):541-57.

  40. Serrano O. Bioinformática: una brecha en la formación en el Sistema Nacional de Salud. Educ Méd Super. 2012 [citado 1 Abr 2014];26(1). Disponible en: http://www.ems.sld.cu/index.php/ems/article/view/13/13

  41. Haspel RL, Arnaout R, Briere L, Kantarci S, Marchand K, Tonellato P, et al. Training Pathology Residents in Genomics and Personalized Medicine. Am J Clin Pathol. 2010;133:832-4.

  42. Founds SA. Introducing Systems Biology for Nursing Science. Biol Res Nurs. 2009;11:73.

  43. Dudley JT, Butte AJ. A Quick Guide for Developing Effective Bioinformatics Programming Skills. PLoS Comput Biol. 2009;5(12):e1000589.

  44. Evans JP, Dale DC, Fomous C. Preparing for a Consumer-Driven Genomic Age. N Engl J Med. 2010;363(12):1099-1103.

  45. Lardoeyt Ferrer R. Estudio psicopedagógico, social y clínico genético de la discapacidad en países del ALBA. Rev Cubana Genética Comun. 2011 [citado 1 Abr 2014];5(2). Disponible en: http:/www.bvs.sld.cu/revistas/rcgc/v5n2- 2/rcgc010111.html

  46. Herrera R, Almaguer M, Chipi J, Toirac X, Martínez O, Castellanos O, et al. Prevalence of Obesity and its Association with Chronic Kidney Disease, Hypertension and Diabetes Mellitus. Isle of Youth Study (ISYS), Cuba. MEDICC Rev. 2008 [cited 2014 Abr 1];10(2). Available from: http://www.medicc.org/mediccreview/index.php?issue=4&id=30&a=vahtml

  47. Fernández Montequín JI, Betancourt BY, Leyva Gonzalez G, Mola EL, Galán Naranjo K, Ramírez Navas M, et al. Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure. Internat Wound J. 2009 [cited 2014 Abr 1];6:67-72. Available from: http://www.onlinelibrary.wiley.com/doi/10.1111/j.1742- 481X.2008.00561.x/full

  48. Beldarraín E. Poliomyelitis and its elimination in Cuba: an historical overview. MEDICC Rev. 2013 [cited 2014 Abr 1];15(2):30-6. Available from: http://www.medicc.org/mediccreview/index.php?issue=24&id=302&a=vahtml

  49. Kannisto V, Christensen K, Vaupel JW. No increased mortality in later life for cohorts born during famine. Am J Epidemiol. 1997;1;145(11):987-94.

  50. Magnusson PK, Almqvist C, Rahman I, Ganna A, Viktorin A, Walum H, et al. The Swedish Twin Registry: establishment of a biobank and other recent developments. Twin Res Hum Genet. 2013 [cited 2014 Abr 1];16(1):317-29. Available from: http:/www.journals.cambridge.org/action/displayFulltext?type=6&fid=8831288&jid =THG&volumeId=16&issueId=01&aid=8831287&bodyId=&membershipNumber=&s ocietyETOCSession=&fulltextType=RA&fileId=S1832427412001041 _________________________ a: Disponible en: http://www.genomemedicine.com/series/participatory b: Disponible en: http://www.nar.oxfordjournals.org/content/42/D1.toc c: Disponible en: http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm 083378.htm d: Disponible en: http://www.cdc.gov/genomics/gtesting/tier.htm




2020     |     www.medigraphic.com